Estimating the magnitude and healthcare costs of melanoma in situ and thin invasive melanoma overdiagnosis in Australia

Lindsay D, Bell KJL, Olsen CM, Whiteman DC, Pathirana T, Collins LG.

Krista Verlis 26/3/24 Krista Verlis 26/3/24

Using the Behaviour Change Wheel to identify barriers and targeted strategies to improve adherence in randomised clinical trials: The example of MEL-SELF trial of patient-led surveillance for melanoma

Deonna M. Ackermann, Jolyn K. Hersch, Monika Janda, Karen Bracken, Robin M. Turner, Katy J.L. Bell